Thrombopoietin/MPL signaling in endocardial endothelium
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-03 — Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.: Preclinical study shows JAK2V617F-mutant hematopoiesis under cardiometabolic stress upregulates endocardial thrombopoietin/MPL signaling to drive cardiac microvascular disease, with anti-MPL neutralizing antibody reversing the phenotype — establishing endocardial MPL as a targetable non-hematopoietic effector of MPN-driven cardiac injury. (novelty: 4)